Agustini, Bruno http://orcid.org/0000-0001-8735-2401
Lotfaliany, Mojtaba
Mohebbi, Mohammadreza
Woods, Robyn L.
McNeil, John J.
Nelson, Mark R.
Shah, Raj C. http://orcid.org/0000-0001-9706-9730
Murray, Anne M.
Reid, Christopher M.
Tonkin, Andrew
Ryan, Joanne http://orcid.org/0000-0002-7039-6325
Williams, Lana J.
Forbes, Malcolm P.
Berk, Michael
Funding for this research was provided by:
Deakin University
Alfred Deakin Postdoctoral Research Fellowship
Department of Health | National Health and Medical Research Council (1136372, 1174060, 1156072)
Article History
Received: 19 August 2021
Accepted: 10 March 2022
First Online: 19 April 2022
Competing interests
: The authors declare the following potential competing interests. M.B. has received grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, NHMRC, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation; has been a speaker for AstraZeneca, Lundbeck, Merck and Pfizer; and served as a consultant to Allergan, AstraZeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier—all unrelated to this work. M.R.N. is member of the Novartis lipids advisory board and received travel and advisory board support from Bayer AG, who provided product for the ASPREE study. A.T. has received honoraria for Safety Monitoring Committee or Advisory Board participation, or lectures from Amgen, Boehringer-Ingelheim, The Medicines Group, Novartis, Pfizer and Merck; and research support from Bayer for materials in ASPREE—all unrelated to this work. These funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.